Needham & Company Maintains Bullish View on Sarepta Therapeutic (SRPT) Following Results and Eteplirsen Regulatory Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. DFTX
8. KR
9. MSTR
10. HOOD

Go back to Needham & Company Maintains Bullish View on Sarepta Therapeutic (SRPT) Following Results and Eteplirsen Regulatory Update

Sarepta Therapeutics (SRPT) Posts Smaller Q3 Loss, Sees Submitting Eteplirsen NDA in Mid-2015

November 6, 2014 7:05 AM EST

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.70), $0.26 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $3.07 million.

In light of the recent FDA guidance for the eteplirsen NDA, the Company has reduced planned expenditures for the... More